Follow-up studies should address whether RANKL is capable of overriding the intracellular machinery responsible for removing dangerous cells (e.g., P53-mediated apoptosis of cancer cells) (Dashzeveg and Yoshida, 2015). Here, TP53 is linked to cancer.